TYK MEDICINES-B: The ESMO 2025 Annual Meeting announced multiple positive clinical data for CDK inhibitors
TYK MEDICINES-B announced that the early clinical study results of its three CDK inhibitors, TYK-00540, TY-2699a, and TY-302, will be presented in poster format at the ESMO Annual Meeting held in Berlin, Germany, from October 17-21, 2025. The ESMO Annual Meeting is an important academic event in the global oncology field, bringing together numerous top experts to discuss clinical challenges and share cutting-edge advancements
According to the Zhitong Finance APP, TYK MEDICINES-B (02410) announced that the company's board of directors is pleased to report the early clinical research results of three drugs in the field of cell cycle protein-dependent kinase inhibitors (CDKi), namely TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i), which were presented in poster form at the European Society for Medical Oncology (ESMO) annual meeting.
The ESMO 2025 annual meeting will be held from October 17-21, 2025, local time, in Berlin, Germany. As one of the most influential academic events in the field of oncology globally, the ESMO annual meeting attracts many top experts and scholars from academia, providing a platform for discussing clinical challenges and sharing cutting-edge advancements
